FDA Inspection 1112939 — Jiangsu Hengrui Medicine Co., Ltd
The FDA completed an inspection of Jiangsu Hengrui Medicine Co., Ltd on November 8, 2019 in Shanghai. The inspection was classified NAI (No Action Indicated — no objectionable conditions were found). Product area: Drugs.
Inspection Details
- Classification
- No Action Indicated (NAI) (NAI)
- End Date
- November 8, 2019
- Fiscal Year
- 2020
- Product Type
- Drugs
- Project Area
- Bioresearch Monitoring
- Location
- Shanghai (China)
Additional Details
Postmarket Adverse Drug Experience (PADE)